{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:50:29Z","timestamp":1777553429319,"version":"3.51.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Without head-to-head trials comparing talazoparib plus enzalutamide (TALA+ENZA), olaparib plus abiraterone acetate and prednisone (OLAP+AAP), and niraparib plus abiraterone acetate and prednisone (NIRA+AAP) as first-line treatments for metastatic castration-resistant prostate cancer (mCRPC), treatment selection remains challenging. This study estimated the relative efficacy of TALA+ENZA vs OLAP+AAP and NIRA+AAP in unselected, homologous recombination repair (HRR)-deficient, and BRCA-mutated (BRCAm) populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Unanchored matching-adjusted indirect comparisons (MAICs) were conducted using individual patient data from TALAPRO-2 (TALA+ENZA) and published summary-level data from PROpel (OLAP+AAP) and MAGNITUDE (NIRA+AAP). TALAPRO-2 patients meeting PROpel\/MAGNITUDE eligibility criteria were included; remaining patients were reweighted to align on key baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for radiographic progression-free survival (rPFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In unselected patients, TALA+ENZA significantly prolonged rPFS vs OLAP+AAP (HR: 0.747; 95% CI, 0.583, 0.957), with no OS difference (HR: 0.821; 95% CI, 0.649, 1.039). In HRR-deficient patients, TALA+ENZA significantly prolonged rPFS vs OLAP+AAP (HR: 0.648; 95% CI, 0.423, 0.992), with no OS difference (HR: 0.834; 95% CI, 0.569, 1.223). Comparisons with OLAP+AAP in BRCAm were infeasible. Compared with NIRA+AAP, TALA+ENZA significantly prolonged rPFS and OS in HRR-deficient (HR: 0.406; 95% CI, 0.251, 0.655; HR: 0.554; 95% CI, 0.340, 0.902) and BRCAm patients (HR: 0.394; 95% CI, 0.222, 0.698; HR: 0.472; 95% CI, 0.247, 0.902).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MAICs showed improved clinical benefit with TALA+ENZA vs OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag143","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:27:56Z","timestamp":1776166076000},"source":"Crossref","is-referenced-by-count":0,"title":["Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations"],"prefix":"10.1093","volume":"31","author":[{"given":"Elena","family":"Castro","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, i+12 Biomedical Research Institute . Hospital Universitario 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 , Burlington, Ontario, L7N 3H8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Paganelli","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 , Burlington, Ontario, L7N 3H8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Haltner","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 , New York, NY, 10018,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neo","family":"Su","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY, 10001,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Kirker","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY, 10001,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Chang","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , New York, NY, 10001,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1415-8055","authenticated-orcid":false,"given":"Imtiaz A","family":"Samjoo","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 , Burlington, Ontario, L7N 3H8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026042814012610700_oyag143-B1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-020-00978-z","article-title":"Novel therapies are changing treatment paradigms in metastatic prostate cancer","volume":"13","author":"Powers","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026042814012610700_oyag143-B2","doi-asserted-by":"crossref","first-page":"1159557","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"key":"2026042814012610700_oyag143-B3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ijms25010078","article-title":"Synthetic lethality by co-inhibition of androgen receptor and polyadenosine diphosphate-ribose in metastatic prostate cancer","volume":"25","author":"Calabrese","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026042814012610700_oyag143-B4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"key":"2026042814012610700_oyag143-B5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"2026042814012610700_oyag143-B6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026042814012610700_oyag143-B7","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"2026042814012610700_oyag143-B8","author":"EMA","year":"2025"},{"key":"2026042814012610700_oyag143-B9","author":"FDA","year":"2023"},{"key":"2026042814012610700_oyag143-B10","author":"EMA","year":"2025"},{"key":"2026042814012610700_oyag143-B11","author":"FDA","year":"2023"},{"key":"2026042814012610700_oyag143-B12","author":"EMA","year":"2024"},{"key":"2026042814012610700_oyag143-B13","author":"FDA","year":"2023"},{"key":"2026042814012610700_oyag143-B14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41391-024-00924-x","article-title":"Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison","volume":"28","author":"Castro","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026042814012610700_oyag143-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2026042814012610700_oyag143-B16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026042814012610700_oyag143-B17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2026042814012610700_oyag143-B18","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026042814012610700_oyag143-B19","doi-asserted-by":"crossref","first-page":"oyae237","DOI":"10.1093\/oncolo\/oyae237","article-title":"Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer","volume":"30","author":"Castro","year":"2025","journal-title":"Oncologist"},{"key":"2026042814012610700_oyag143-B20","author":"Nice","year":"2024"},{"key":"2026042814012610700_oyag143-B21","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"2026042814012610700_oyag143-B22","author":"ODAC","year":"2023"},{"key":"2026042814012610700_oyag143-B23","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/annonc\/mdy406","article-title":"Development and validation of a prognostic model for overall survival in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer","volume":"29","author":"Armstrong","year":"2018","journal-title":"Ann Oncol"},{"key":"2026042814012610700_oyag143-B24","author":"Phillippo","year":"2016"},{"key":"2026042814012610700_oyag143-B25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"2026042814012610700_oyag143-B26","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026042814012610700_oyag143-B27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"key":"2026042814012610700_oyag143-B28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"2026042814012610700_oyag143-B29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026042814012610700_oyag143-B30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2026042814012610700_oyag143-B31","author":"Latimer","year":"2011"},{"key":"2026042814012610700_oyag143-B32","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s12094-024-03506-4","article-title":"Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"26","author":"Ai","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"2026042814012610700_oyag143-B33","doi-asserted-by":"crossref","first-page":"1225033","DOI":"10.3389\/fendo.2023.1225033","article-title":"Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026042814012610700_oyag143-B34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.21037\/cco-24-82","article-title":"Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"2026042814012610700_oyag143-B35","doi-asserted-by":"crossref","first-page":"1290990","DOI":"10.3389\/fphar.2023.1290990","article-title":"Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026042814012610700_oyag143-B36","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jval.2018.03.012","article-title":"Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic\/mildly symptomatic metastatic castration-resistant prostate cancer","volume":"21","author":"McCool","year":"2018","journal-title":"Value Health"},{"key":"2026042814012610700_oyag143-B37","doi-asserted-by":"crossref","first-page":"1378993","DOI":"10.3389\/fonc.2024.1378993","article-title":"Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"key":"2026042814012610700_oyag143-B38","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s12325-024-02918-6","article-title":"Feasibility of indirect treatment comparisons between niraparib plus abiraterone acetate and other first-line poly ADP-Ribose polymerase inhibitor treatment regimens for patients with BRCA1\/2 mutation-positive metastatic castration-resistant prostate cancer","volume":"41","author":"De Santis","year":"2024","journal-title":"Adv Ther"},{"key":"2026042814012610700_oyag143-B39","author":"FDA","year":"2020"},{"key":"2026042814012610700_oyag143-B40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s43441-025-00848-1","article-title":"Ensuring quality and interpretability of progression free survival and overall survival in oncology clinical trials","volume":"59","author":"He","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"2026042814012610700_oyag143-B41","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1080\/14796694.2025.2526324","article-title":"Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC","volume":"21","author":"Armstrong","year":"2025","journal-title":"Future Oncol"},{"key":"2026042814012610700_oyag143-B42","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1007\/s00432-022-04562-5","article-title":"Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors","volume":"149","author":"Atallah","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026042814012610700_oyag143-B43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"key":"2026042814012610700_oyag143-B44","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag143\/68099561\/oyag143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag143\/68099561\/oyag143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag143\/68099561\/oyag143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:01:39Z","timestamp":1777399299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag143\/8657073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag143","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,10]]},"article-number":"oyag143"}}